# Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers

> **NCT00990990** · PHASE1 · COMPLETED · sponsor: **Sequella, Inc.** · enrollment: 59 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** PNU-100480
- **DRUG:** Placebo
- **DRUG:** PNU-100480
- **DRUG:** Placebo
- **DRUG:** PNU-100480
- **DRUG:** Placebo
- **DRUG:** PNU-100480
- **DRUG:** Placebo
- **DRUG:** PNU-100480
- **DRUG:** Placebo
- **DRUG:** PNU-100480
- **DRUG:** Placebo
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT00990990
- **Lead sponsor:** Sequella, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2013-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00990990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00990990, "Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00990990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*